Gainers
Celyad Oncology SA (NASDAQ: CYAD) jumped 187% to $2.30 after gaining 21% on Friday. Celyad Oncology, last month, decided to discontinue the development of its remaining clinical program CYAD-211.
Tritium DCFC Limited (NASDAQ: DCFC) shares are trading higher today after the company reported its full-year 2022 preliminary sales and issued full-year 2023 sales guidance.
Secured the largest order from a single customer in Company history with a new order from bp (NYSE:BP) for deployment across the United States, United Kingdom, Europe, and Australia.